Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Kim C. Honselmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5699-2286; OpenAlex author ID A5004055245. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 5 papers · 2021: 4 papers · 2022: 3 papers · 2023: 5 papers · 2024: 2 papers · 2025: 4 papers · 2026: 2 papers

Papers 31

  1. Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-026-01663-z↗
  2. Octogenarians and Pancreatic Cancer: Is Surgery Always the Right Choice? Co-author DOI 10.3390/cancers18152423↗
  3. An R0 resection margin does improve overall survival after PDAC resection- real-world evidence from 6.000 cases from the German Cancer Registry Group. Co-author DOI 10.1016/j.ejso.2025.109693↗
  4. [Innovations in the German Guideline for Pancreatic Cancer]. First author DOI 10.1055/a-2529-5372↗
  5. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  6. Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03262-x↗
  7. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national re… Co-author DOI 10.1016/j.surg.2023.11.004↗
  8. Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic D… Co-author DOI 10.3390/cancers16112016↗
  9. A Tumor Microenvironment Model of Pancreatic Cancer to Elucidate Responses toward Immunotherapy. Co-author DOI 10.1002/adhm.202201907↗
  10. Recent onset diabetes is associated with better survival in pancreatic ductal adenocarcinoma-An analysis of preoperative symptoms within the DGAV StuDoQ|Pancre… Co-author DOI 10.1016/j.surg.2023.04.042↗
  11. Overexpression of integrin alpha 2 (ITGA2) correlates with poor survival in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1136/jclinpath-2022-208176↗
  12. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations. Co-author DOI 10.3389/fonc.2023.1230382↗
  13. Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response. Co-author DOI 10.3390/cells12040587↗
  14. [Incidence, Treatment and Survival in Pancreatic Cancer- Data of the Nationwide Oncological Quality Conference from a Surgical Perspective]. Last author DOI 10.1055/a-1768-1012↗
  15. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Co-author DOI 10.1097/sla.0000000000005433↗
  16. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cance… Co-author DOI 10.3390/cancers14040868↗
  17. Radiological prediction of portal vein infiltration in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.015↗
  18. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1. Co-author DOI 10.1073/pnas.2003014118↗
  19. Postoperative Outcomes of Tangential versus Segmental Resection and End-to-end Reconstruction of the Superior Mesenterico-Portal Vein During Pancreatoduodenect… Co-author DOI 10.21873/anticanres.15329↗
  20. Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis. Co-author DOI 10.3791/62541↗
  21. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  22. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  23. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02414-9↗
  24. Alignment of stroma fibers, microvessel density and immune cell populations determine overall survival in pancreatic cancer-An analysis of stromal morphology. Co-author DOI 10.1371/journal.pone.0234568↗
  25. Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients-Proposal of a New Simplified Borderline Resectabilit… Co-author DOI 10.3390/cancers12040882↗
  26. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  27. Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.0979↗
  28. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. First author DOI 10.3390/cancers10090316↗
  29. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. Co-author DOI 10.1371/journal.pone.0182855↗
  30. Regulation mechanisms of the hedgehog pathway in pancreatic cancer: a review. Co-author DOI 10.6092/1590-8577/2894↗
  31. Neoadjuvant therapy in pancreatic cancer: review article. Co-author DOI 10.6092/1590-8577/2940↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tobias Keck · 22 shared papers, 2015–2026 · strength 3.25
  2. Louisa Bolm · 19 shared papers, 2020–2026 · strength 2.84
  3. Ulrich Friedrich Wellner · 21 shared papers, 2015–2026 · strength 2.82
  4. Rüdiger Braun · 14 shared papers, 2021–2026 · strength 2.21
  5. Steffen Deichmann · 14 shared papers, 2015–2026 · strength 2.00
  6. Hryhoriy V. Lapshyn · 11 shared papers, 2020–2026 · strength 1.62
  7. Lennart von Fritsch · 4 shared papers, 2024–2026 · strength 1.00
  8. Keith D. Lillemoe · 8 shared papers, 2017–2025 · strength 0.87
  9. Carlos F. Fernandez-del Castillo · 7 shared papers, 2017–2025 · strength 0.81
  10. Thaer S. A. Abdalla · 4 shared papers, 2024–2026 · strength 0.75
  11. Natalie Petruch · 5 shared papers, 2021–2025 · strength 0.73
  12. Andrew Scott Liss · 5 shared papers, 2017–2025 · strength 0.58
  13. Ekaterina Petrova · 5 shared papers, 2020–2022 · strength 0.55
  14. Dirk Bausch · 6 shared papers, 2015–2021 · strength 0.54
  15. Benedikt Färber · 3 shared papers, 2023–2026 · strength 0.52
  16. Andrew Louis Warshaw · 5 shared papers, 2017–2025 · strength 0.51
  17. Cristina Rosa Ferrone · 5 shared papers, 2018–2023 · strength 0.50
  18. Motaz Qadan · 4 shared papers, 2019–2024 · strength 0.46
  19. Mari A. Mino-Kenudson · 4 shared papers, 2017–2025 · strength 0.45
  20. Taisuke Baba · 3 shared papers, 2022–2025 · strength 0.44
  21. Jon Michael Harrison · 3 shared papers, 2022–2025 · strength 0.44
  22. Thomas P. Hank · 3 shared papers, 2020–2025 · strength 0.39
  23. David Tsai Ting · 3 shared papers, 2020–2025 · strength 0.38
  24. Benjamin Heckelmann · 2 shared papers, 2023–2026 · strength 0.37
  25. Jens Uwe Marquardt · 2 shared papers, 2023–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.